In direct-compression orodispersible tablet manufacture, the blended sweetener system functions as a water-soluble crystalline filler-binder and disintegration enhancer rather than as a simple taste modifier. The polyol carrier fraction—typically a co-processed mannitol-sorbitol matrix—is incorporated at 70–90% w/w of finished tablet-core mass when the unit API dose is below 50 mg, while the high-intensity sweetener fraction is restricted to 0.05–0.8% w/w to prevent local concentration gradients that produce delayed bitterness. For freeze-dried ODT platforms, the loading is reduced to 25–50% w/w because gelatin, pullulan, or starch-based matrices contribute mechanical resilience after lyophilization. Because the blend itself is not a compendial monograph article, each component must conform to its respective USP-NF or Ph. Eur. monograph; the finished ODT is then released against USP <701> disintegration using a basket-rack assembly in 900 mL purified water at 37 ± 2 °C with an ODT-specific limit of ≤60 s, USP <711> dissolution using paddle or basket apparatus with immediate-release criteria, USP <905> uniformity of dosage units, and USP <1216> friability with a limit of ≤1.0%. Direct compression is performed on a rotary tablet press with 10.5 mm flat-faced beveled-edge tooling; main compression force is maintained at 5–15 kN, precompression force at 3–5 kN, turret speed at 30–80 rpm, and forced-feeder paddle speed at 20–40 rpm. Tablet hardness is held at 30–60 N, and ejection force is kept below 800 N to avoid lamination at the die wall. The blend is processed at 20–35% RH; when ambient humidity exceeds 60% RH, the mix is pre-dried in a fluid-bed dryer at 40–50 °C until loss-on-drying is ≤1.0%. Particle-size distribution is controlled at D50 100–180 μm and D90 below 355 μm; a Hausner ratio of 1.15–1.35 and Carr index of 15–25 are necessary for consistent die filling. Terminal finished types include ondansetron, loperamide, rizatriptan, loratadine, and paracetamol orodispersible tablets produced on high-speed rotary lines.

Chewable Antacid Granulation and Sweetener Particle Size Distribution Limits

Wet granulation with the blended sweetener at 30–60% w/w of the granulated mass changes the compaction profile of aluminium hydroxide–magnesium hydroxide antacid tablets less than the particle-size distribution does; in vitamin and mineral chewables the bulk polyol loading can reach 50–80% w/w when the active premix is highly potent. The high-intensity fraction is added at 0.05–0.5% w/w, typically as a pre-blend with the binder solution or with the dry filler to avoid localized sweetness variance. Granulation is carried out in a high-shear mixer-granulator with main impeller speed 150–300 rpm and chopper speed 1000–2000 rpm; purified water or a maltitol solution is sprayed to a granulation endpoint moisture of 12–18%. The wet mass is milled through a 1.5 mm screen, dried in a fluid-bed dryer at inlet air 60–80 °C to a final LOD of 1.0–2.0%, and milled again through 0.8–1.5 mm before lubrication with 0.5–1.0% w/w magnesium stearate. Compression is performed at 8–22 kN, with tablet hardness maintained at 60–100 N and friability at ≤0.8% under USP <1216>. The particle-size distribution is a critical operational boundary: D50 below 75 μm produces punch sticking on high-speed turrets, while D50 above 250 μm creates a gritty mouthfeel and increases patient complaints; the working window is therefore D50 125–250 μm with D10 above 45 μm and D90 below 500 μm. Release testing includes USP <905>, USP <711>, and USP <232>/USP <233> elemental impurity verification under ICH Q3D risk assessment. Terminal finished types include calcium carbonate antacids, aluminium hydroxide–magnesium hydroxide chewable tablets, and calcium/vitamin D mineral chewables.

When Effervescent Granules Require Acid-Stable High-Intensity Sweetener Fractions

To prevent premature acid-base reaction in effervescent granulation, the bulk polyol fraction is incorporated at 50–85% w/w of granule mass, while the acid-stable high-intensity fraction is held at 0.02–0.5% w/w; aspartame is excluded from citric acid-containing granulations because diketopiperazine formation accelerates at pH below 4.0 and causes sweetness loss. Granulation is performed as a non-aqueous process using dehydrated ethanol or isopropanol as the binding solvent to prevent premature reaction between citric acid, tartaric acid, and sodium bicarbonate. In a fluid-bed top-spray system, inlet air temperature is maintained at 35–45 °C, product temperature at 28–35 °C, and spray rate is adjusted to keep granule moisture below 1.0%; residual solvent is then controlled to ICH Q3C limits by final drying at 40–50 °C until loss-on-drying is ≤0.5%. The acid and carbonate components are either granulated as separate populations and blended before sachet filling, or co-processed with anhydrous citric acid and low-water-activity conditions; packaging requires cold-form aluminium/aluminium laminate with a moisture vapour transmission rate controlled under USP <671>. Effervescent granules are tested for disintegration by USP <701> and drug release by USP <711>, with uniformity by USP <905>; elemental impurities are assessed under USP <232>/USP <233>. Terminal finished types include oral electrolyte effervescent granules, vitamin C effervescent tablets, cough-and-cold granule sachets, and antacid/analgesic powder formulations.

When a dry syrup is reconstituted, the blended sweetener must simultaneously serve as bulk carrier, crystallization inhibitor, and palatability anchor before and after aqueous dilution. In the dry powder, the bulk polyol/carbohydrate fraction is added at 40–80% w/w, and the high-intensity fraction at 0.05–0.5% w/w; after reconstitution as an oral liquid vehicle, total sweetening solids may reach 20–70% w/v depending on viscosity, pH, and sweetness targets. The dry materials are sieved through 600 μm, blended in a bin blender at 10–20 rpm for 20–30 min, and filled into HDPE bottles at 25–35% RH; the reconstitution vehicle is prepared in a jacketed stainless-steel mixing vessel heated to 80–90 °C for 30 min when sucrose is present, cooled to 25–30 °C, adjusted to pH 4.5–6.5, and homogenized at 1000–3000 rpm. Nonreducing polyol grades are preferred when the API is a primary amine because reducing sugars undergo Maillard reaction; with sucrose-containing systems, prolonged storage at pH below 4.5 produces invert sugar and changes both sweetness intensity and osmolality. Microbial quality is controlled by USP <1111> nonsterile product limits, USP <51> antimicrobial effectiveness testing, and 21 CFR 211.166 stability testing; USP <232>/USP <233> elemental impurity procedures apply to all components under ICH Q3D. Terminal finished types include pediatric antibiotic dry suspensions, oral rehydration salt powders, antidiarrheal oral solutions, and antacid suspensions.

Does Powder-Filling Uniformity Drift When the Polyol Fraction Exceeds 60% in Capsule Blends?

Formulation data from dosator-based capsule filling lines indicate that the practical upper limit is not a single number but a function of polyol particle-size distribution and water activity. The blended sweetener is loaded at 10–65% w/w of the powder mass for hard gelatin or HPMC capsules; beyond 60% w/w polyol content, weight variability tends to increase if the raw blend contains high-fines mannitol or if ambient RH exceeds 40%. The high-intensity fraction remains at 0.05–0.3% w/w and is geometrically diluted through a 250 μm screen before addition to the main powder blend. Processing involves sieving the total blend through 600 μm, mixing in an IBC bin blender at 15–20 rpm for 20–25 min, and filling on a dosator-type capsule machine at 60,000–100,000 capsules/h or on a tamping-pin machine with dosing-disc compression stations. Fill weight is set between 200–750 mg across capsule sizes 00–4, with weight variation RSD held at ≤2.0%. Flow properties are maintained with a Hausner ratio of 1.10–1.30 and Carr index of 10–25; if the formulation contains more than 50% w/w sorbitol, the blend is pre-dried and lubricated with 0.5% w/w magnesium stearate to reduce sticking. Release testing includes USP <905> uniformity of dosage units, USP <711> dissolution, and USP <232>/USP <233> elemental impurity verification. Published data for this specific blend configuration is limited; robust formulation development should therefore include a three-factor DoE covering polyol particle size, water activity, and press lubrication. Terminal finished types include enzyme capsules, probiotic capsules, oral rehydration powder capsules, and amino acid blend capsules.

Injectable Tonicity Anomalies: The Osmolality Gap Between Compendial Limits and Polyol Loading

Because high-intensity sweetener fractions lack parenteral monograph support, injectable applications of the blended sweetener system require a deliberate separation of the polyol fraction from the high-intensity fraction. For parenteral use, only compendial polyol/carbohydrate components—mannitol, dextrose, or sucrose—are admissible; the high-intensity sweetener fraction is omitted entirely because no parenteral monograph supports its use. In lyophilized parenteral formulations, mannitol or dextrose is incorporated at 5–15% w/v before filling; mannitol is preferred for albumin-free proteins and peptides because it forms a crystalline cake, while dextrose is restricted to low-temperature processing and non-amine APIs due to reducing-end Maillard reactivity. Liquid isotonic adjustment uses dextrose 5% w/v or mannitol 1–5% w/v, with target osmolality of 270–328 mOsmol/kg under USP <785>. The solution is prepared in Water for Injection at 20–25 °C, pH-adjusted, passed through a 0.22 μm PVDF or PES sterilizing-grade filter, and aseptically filled under EU GMP Annex 1 conditions. For lyophilized products, the cycle includes freezing to -40 °C to -50 °C, annealing at -20 °C for 2–4 h to crystallize mannitol and prevent vial breakage, primary drying at shelf -20 °C to -10 °C with chamber pressure 50–150 mTorr, and secondary drying at 25–40 °C to residual moisture ≤1.0%. Particulate matter is controlled by USP <788>, subvisible particulates in protein injections by USP <787>, visible particulates by USP <790>, and sterility by USP <71>. Terminal finished types include lyophilized peptide APIs, monoclonal antibody powders, vaccine cakes, cytotoxic drug powders for injection, and antibiotic injectable powders. Operational boundary: if annealing is omitted, mannitol crystallization remains incomplete and the lyophilized cake collapses; dextrose-containing formulations should not be autoclaved with amine-containing APIs because caramelization and Maillard adduct formation occur under terminal sterilization conditions.